Core Viewpoint - Haixi New Drug (02637) experienced a significant stock price increase, rising over 12% to a peak of 114.9 HKD, which is more than 30% above its IPO price of 86.4 HKD, indicating strong market interest and investor confidence in the company [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has received approval for 15 generic drug products, with a product portfolio that spans multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting diseases in oncology, ophthalmology, and respiratory systems [1] Future Plans - The company plans to actively explore collaboration opportunities with multinational corporations (MNCs) to enhance its international clinical research and commercialization capabilities [1]
海西新药一度涨超12% 较招股价涨超三成 仿制药、创新药双线布局